ACTU (Actuate Therapeutics) Total Stockholders Equity: $3.78 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.69
View Full Analysis

What is Actuate Therapeutics Total Stockholders Equity?

Actuate Therapeutics ACTU -2.02% 14 Total Stockholders Equity is $3.78 Mil as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.

Actuate Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $3.78 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Actuate Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $0.16. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Actuate Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.00.

Actuate Therapeutics  (NAS:ACTU) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Actuate Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.784-0)/23.712
=0.16

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Actuate Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 3.784
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Total Stockholders Equity Related Terms

Actuate Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Total Stockholders Equity Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
-75.31 -99.63 0.10 7.92

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.09 -2.65 10.94 7.92 3.78
ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $3.78 Mil mean?
Actuate Therapeutics (ACTU) has a Total Stockholders Equity of $3.78 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' Total Stockholders Equity too high?
Actuate Therapeutics' current Total Stockholders Equity is $3.78 Mil. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Total Stockholders Equity compare to RNXT and ESLA?
Actuate Therapeutics' Total Stockholders Equity of $3.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Actuate Therapeutics and its competitors. Actuate Therapeutics's current Total Stockholders Equity is $3.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Total Stockholders Equity of $3.78 Mil. The current Total Stockholders Equity is $3.78 Mil. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Total Stockholders Equity is $3.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.69
Price